Literature DB >> 23706986

NICE guidance on bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer.

Pilar Pinilla-Dominguez, Joanna Richardson, Janet Robertson, Jane Adam.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23706986     DOI： 10.1016/S1470-2045(13)70247-X

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  2 in total

1.  Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Paul Tappenden; Sue Harnan; Shijie Ren; Praveen Thokala; Ruth Wong; Clara Mukuria; Clare Green; Simon Pledge; John Tidy
Journal:  Pharmacoeconomics       Date:  2017-01       Impact factor: 4.981

2.  Estimating health-state utility values for patients with recurrent ovarian cancer using Functional Assessment of Cancer Therapy - General mapping algorithms.

Authors:  Robert Hettle; John Borrill; Gaurav Suri; Jerome Wulff
Journal:  Clinicoecon Outcomes Res       Date:  2015-11-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.